Therefore, the association between overexpressed ACVR2B and poor prognosis of patients with sarcoma suggests a possibility of utilizing ACVR2B antagonists in reliving the cachemic effect of sarcoma and the therapy-induced loss of muscle mass, which has not yet been investigated. The gene discussed is ACVR2B; the disease is sarcoma.